Draig Therapeutics, a clinical-stage neuropsychiatry company co-founded by Cardiff University scientists, secured $140 million in Series A funding led by Access Biotechnology. The company focuses on novel oral therapies modulating glutamate and GABA pathways to treat psychiatric diseases like major depressive disorder (MDD), aiming for differentiated profiles without ketamine-like dissociative side effects. The co-founders’ experience includes successful biotech ventures and major neuroscience research institutions. The injection of capital supports pipeline advancement amid a broader pharma industry resurgence in neuroscience investment.